Zuzana Walker

• MD, FRCPsych
• Professor at University College London

Introduction: In a mixed-methods process evaluation embedded within a randomised controlled trial, we aimed to investigate how the APPLE-Tree secondary dementia prevention intervention might support behavioural and lifestyle goal attainment, through determining contexts influencing engagement and testing intervention theoretical assumptions. Method...

BACKGROUND Digital biomarkers are gaining interest as proxy markers for mental health as they enable passive and continuous data collection. However, the association between digital biomarkers of health and anxiety, both generalised anxiety disorder and anxiety symptoms, remains unknown. OBJECTIVE This systematic review and meta-analysis aimed to...

Introduction: DREAMS-START is a multicomponent intervention targeting sleep disturbance in people with dementia. To enhance understanding of the DREAMS-START randomised controlled trial, which showed improved sleep in the intervention compared to the control arm, we conducted a process evaluation exploring (i) DREAMS-START delivery, (ii) behaviour...

Question: What is the current evidence base for the association between digital biomarkers from wrist-worn wearables, loneliness and social isolation in adults? Study selection and analysis: We systematically searched six databases from inception to 24th September, 2024. We narratively synthesised findings and pooled effect sizes using random-effec...

Background With global dementia prevalence estimated to reach 139 million by 2050,(1) early detection of dementia‐causing diseases is crucial for promoting preventative interventions. Wearable technologies have the potential to detect early signs; however, they need to be acceptable amongst users. We explored user’s perspectives on the acceptabilit...

Background Sleep disturbance is common and distressing for people with dementia, with no known safe, effective treatments. We previously developed and delivered DREAMS‐START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives), a multimodal non‐pharmacological intervention, and demonstrated feasibility and acceptability. This randomised co...

Background Anxiety, both generalised anxiety disorder and anxiety symptoms, has been recognised as a risk factor and prodromal symptom of dementia. Digital biomarkers are gaining interest as proxy markers for mental health because they enable passive and continuous data collection, allowing for early detection. However, the association between digi...

Background With global dementia prevalence estimated to reach 139 million by 2050,⁽¹⁾ early detection of dementia‐causing diseases is crucial for promoting preventative interventions. Wearable technologies have the potential to detect early signs; however, they need to be acceptable amongst users. We explored user’s perspectives on the acceptabilit...

Background Alzheimer’s disease is a devastating neurodegenerative disorder with a complex pathogenesis. One main pathological feature utilised in diagnosis is neurodegeneration or neuronal injury, which is reflected in reductions in cerebral glucose metabolism measured by [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). Here w...

Psychological characteristics are associated with varying dementia risk and protective factors. To determine whether these characteristics aggregate into psychological profiles and whether these profiles differentially relate to aging health, we conducted a cross-sectional investigation in two independent middle-aged (51.4 ± 7.0 years (mean ± s.d.)...

Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all studies to date have implemented a retrospective case collection, and challenging cases were generally...

Abstract Objectives To explore the effectiveness of an adapted 14-week cognitive stimulation therapy (CST) protocol on psychoaffective symptoms and quality of life (QOL) for people living with mild dementia. Method The sample for this pragmatic study were people with dementia who underwent CST between May 2016 and September 2022 during routine hea...

Co-pathologies are common in dementia with Lewy bodies and other dementia disorders. We investigated cerebrovascular and Alzheimer’s disease co-pathologies in patients with dementia with Lewy bodies in comparison with patients with mild cognitive impairment, Alzheimer’s disease, mixed dementia, vascular dementia or Parkinson’s disease with dementia...

Introduction Mental health conditions are associated with cognition and physical function in older adults. We examined whether worry and ruminative brooding, key symptoms of certain mental health conditions, are related to subjective and/or objective measures of cognitive and physical (cardiovascular) health. Methods We used baseline data from 282...

Background The research criteria for subjective cognitive decline (SCD) exclude mild cognitive impairment (MCI), but do not stipulate the use of specific MCI criteria. This study compared different approaches to defining (i.e., excluding) MCI during the ascertainment of SCD, focusing on the impact on dementia incidence rates in SCD. Methods This c...

Data-driven solutions offer great promise for improving healthcare. However, standard clinical neuroimaging data is subject to real-world imaging artefacts that can render the data unusable for computational research and quantitative neuroradiology. T1 weighted structural MRI is used in dementia research to obtain volumetric measurements from corti...

Several studies have demonstrated the high agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support the assessment of less experienced readers and/or in challenging cases. However, all studies to date have implemented a retrospective case collection and challenging cases were g...

INTRODUCTION To support clinical trial designs focused on early interventions, our study determined reliable early amyloid‐β (Aβ) accumulation based on Centiloids (CL) in pre‐dementia populations. METHODS A total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease–Prognostic and Natural History Study (AMYPAD‐PNHS) and Insi...

Objectives Higher-educated patients with Alzheimer disease (AD) can harbor greater neuropathologic burden than those with less education despite similar symptom severity. In this study, we assessed whether this observation is also present in potential preclinical AD stages, namely in individuals with subjective cognitive decline and clinical featur...

Introduction Many people living with dementia experience sleep disturbance and there are no known effective treatments. Non-pharmacological treatment options should be the first-line sleep management. For family carers, relatives’ sleep disturbance leads to interruption of their sleep, low mood and breakdown of care. Our team developed and delivere...

Objectives It is important to determine if cognitive measures identified as being prognostic in dementia research cohorts also have utility in memory clinics. We aimed to identify measures with the greatest power to predict future Alzheimer's disease (AD) dementia in a clinical setting where expensive biomarkers are not widely available. Methods T...

Background Preclinical evidence in transgenic models of Alzheimer’s disease (AD) suggests that liraglutide, a GLP1 analogue, exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and reducing insulin resistance, and increasing the proliferation of neuronal progenitor cells. ELAD is a 12‐month, multi‐centre, r...

Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its ability to predict early amyloid accumulation. Method Longitudinal amyloid‐PET with ¹⁸ F‐flutemetamol and ¹⁸ F‐fl...

Background Magnetic resonance spectroscopy (MRS) is a non‐invasive method of evaluating metabolite levels in the cerebral cortex. Measurable metabolites can provide markers of neuronal damage, glial activation and, neurotransmission, pathological features of Alzheimer’s disease. Here we sought to establish the effectiveness of several metabolites a...

Background Differential diagnosis of dementias in the clinic is challenging, especially in the prodromal phase where early symptoms overlap. Here we prototype a differential diagnosis system based on event‐based modeling of MRI atrophy in two dementias. Method Public data from ADNI, NACC, PPMI, PDBP (N = 1978). Inclusion criteria: baseline T1w‐MRI...

Background Glucose is the primary energy source required for the homeostatic function of the brain. Glucose transporter 1 (GLUT1) present at the blood‐brain barrier is a key regulator of glucose transport into the brain. Reduced GLUT1 expression is shown to exacerbate Alzheimer’s pathology in rodent models. Here we aimed to establish whether there...

Background The present study aimed to explore the association between Apolipoprotein E (APOE) genotype, the main genetic risk factor for sporadic Alzheimer’s Disease (AD), age, and cerebral β‐amyloid (Aβ) aggregation, the earliest pathological event in AD in a large, multicenter, European cohort, the AMYPAD study. Method We included 876 participan...

Background The benefits of the early detection of the neurodegenerative and vascular pathologies which cause dementia are widely acknowledged. These include the opportunity to initiate risk‐reduction strategies, disease‐modifying therapies, and future care planning. However, current pathological biomarkers have several important drawbacks, as they...

Background Depression and anxiety are two frequent neuropsychiatric symptoms in Alzheimer’s disease (AD). Moreover, depressive symptoms and anxiety are frequently associated with greater amyloid deposition and risk of Alzheimer’s dementia. The aim of the present study is to assess the association between anxiety and depression and amyloid burden....

Background No specific clinical rating scale currently exists for Lewy body dementia (LBD). Clinical rating scales developed for other diseases are therefore used instead for LBD clinical trials. However, these scales are not optimized for LBD and may not sufficiently reflect the complex array of LBD‐related phenomenology, making it more difficult...

Background Nearly half of people aged 60+ experience memory impairments that infer an increased risk of dementia. The UK APPLE‐Tree (Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce) trial is evaluating a secondary dementia prevention intervention for people at increased dementia...

Background Timely diagnosis of Alzheimer’s disease (AD) is important for patients, carers and healthcare systems. It is therefore imperative to identify measures with the greatest power to predict future AD dementia. In contrast to research settings, expensive biomarkers are not always available in memory clinics. It is therefore vital to identify...

Background In clinical practice, amyloid‐PET images are visually assessed to determine the presence or absence of amyloid pathology. The expected arrival of disease‐modifying treatments warrants the need for objective quantification of amyloid burden to further support treatment decisions. Here, we investigated whether quantification increases read...

Background Differential diagnosis of dementias in the clinic is challenging, especially in the prodromal phase where early symptoms overlap. Here we prototype a differential diagnosis system based on event‐based modeling of MRI atrophy in two dementias. Method Public data from ADNI, NACC, PPMI, PDBP (N = 1978). Inclusion criteria: baseline T1w‐MRI...

Background Longitudinal amyloid‐PET‐based imaging endpoints are often included in clinical trials, where they provide critical evidence of treatment efficacy. We assessed the longitudinal variability of the Centiloid (CL) scale and its ability to predict early amyloid accumulation. Method Longitudinal amyloid‐PET with 18F‐flutemetamol and 18F‐flor...

INTRODUCTION Sex influences neurodegeneration, but it has been poorly investigated in dementia with Lewy bodies (DLB). We investigated sex differences in brain atrophy in DLB using magnetic resonance imaging (MRI). METHODS We included 436 patients from the European‐DLB consortium and the Mayo Clinic. Sex differences and sex‐by‐age interactions wer...

Background Around 50 million people have dementia worldwide, with nearly 10 million new cases every year. Diagnosis is complex and often relies on expensive and invasive measures, with most patients accessing medical support when they already experience symptoms. Method The Early Detection of Neurodegenerative diseases (EDoN) initiative, spearhead...

Background Higher educated patients with MCI can tolerate more neuropathology than lower educated patients with similar clinical impairment. It is not known whether this observation also accounts for potential preclinical stages of AD, namely subjective cognitive decline plus (SCD+). Method Data of 197 SCD+ individuals, 227 MCI and 157 AD patients...

Background Individuals with subjective cognitive decline (SCD) perceive that their cognition has worsened, but score normally on standardized cognitive tests. It is increasingly recognized that SCD has variable prognosis with the risk of progression to dementia being twice that of age‐matched controls without SCD. This study aimed to characterize a...

Importance: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. Objective: To assess the clinical effect of...

Data-driven solutions offer great promise for improving healthcare. However standard clinical neuroimaging data is subject to real-world imaging artefacts that can render the data unusable for computational research. T1 weighted structural MRI is used in research to obtain volumetric measurements from cortical and subcortical brain regions. However...

Background and objectives Sex is an important contributing factor to neuroimaging phenotypes in brain disorders. However, little is known about the contribution of sex differences to the neurodegeneration in dementia with Lewy bodies (DLB). We investigated sex differences in probable DLB patients by using both visual rating scales of lobar atrophy...

Background Amyloid-β (Aβ) accumulation is considered the earliest pathological change in Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium is a collaborative European framework across European Federation of Pharmaceutical Industries Associations (EFPIA), academic, and ‘Small and Medium-sized enterprise...

Importance Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know the...

IMPORTANCE: Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know th...

Background: The increasing availability of large high-dimensional data from experimental medicine, population-based and clinical cohorts, clinical trials, and electronic health records has the potential to transform dementia research. Our ability to make best use of this rich data will depend on utilisation of advanced machine learning and artific...

The use of standard clinical neuroimaging data for quantitative research is often precluded by imaging artefacts caused by real‐world limitations. For example, partial coverage (cropping) of T1‐weighted MRI scans can occur when a memory clinic prioritises visual ratings on T2‐weighted MRI, and so the T1 scan field‐of‐view is reduced to minimise the...

The increasing availability of large high‐dimensional data from experimental medicine, population‐based and clinical cohorts, clinical trials, and electronic health records has the potential to transform dementia research. Our ability to make best use of this rich data will depend on utilisation of advanced machine learning and artificial intellige...

Amyloid‐PET allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer’s disease. However, this technique is currently not or incompletely reimbursed due to lack of randomized controlled studies demonstrating a clinical impact. AMYPAD‐DPMS is a prospective, multicenter, randomized controlled study. Patients with subj...

Amyloid‐PET allows the assessment of amyloid deposition, one of the main hallmarks of Alzheimer’s disease. However, in most countries, this exam is not routinely used in clinical practice. Several studies have assessed physician‐centered outcomes, yet often without a randomized study design. In addition, the choice to reimburse amyloid‐PET depends...

Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesteras...

Background Older individuals with subjective cognitive decline (SCD) perceive that their cognition has declined but do not show objective impairment on neuropsychological tests. Individuals with SCD are at elevated risk of objective cognitive decline and incident dementia. Non-pharmacological interventions (including mindfulness-based and health se...

Mindfulness-based programs (MBPs) are increasingly utilized to improve mental health. Interest in the putative effects of MBPs on cognitive function is also growing. This is the first meta-analysis of objective cognitive outcomes across multiple domains from randomized MBP studies of adults. Seven databases were systematically searched to January 2...

Background Large-scale trials of multidomain interventions show that modifying lifestyle and psychological risk factors can slow cognitive decline. We aim to determine if a lower intensity, personally tailored secondary dementia prevention programme for older people with subjective or mild objective memory decline, informed by behaviour change theo...

Background and Objectives Self-reflection (the active evaluation of ones thoughts, feelings and behaviours) can confer protection against adverse health outcomes. Its impact on markers sensitive to Alzheimer’s disease (AD), however, is unknown. The primary objective of this cross-sectional study was to examine the association between self-reflectio...

Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairm...

Background Largescale trials of multi-domain interventions show that modifying lifestyle and psychological risk factors can slow cognitive decline. We aim to determine if a lower intensity, personally tailored secondary dementia prevention programme for older people with subjective or mild objective memory decline, informed by behaviour change theo...

Background Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue licensed for the treatment of type 2 diabetes. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the p...

Background Subjective cognitive decline (SCD) denotes self‐reported cognitive concerns in the absence of objective cognitive impairment. Individuals with SCD convert to dementia at twice the annual rate of healthy controls, with relatively poorer cognition in SCD conferring additional risk. Non‐pharmacological interventions are currently undergoing...

Background AMYPAD‐DPMS is a European, multicenter, prospective, interventional, randomized controlled study. It aims to assess clinical utility and cost‐effectiveness of amyloid‐PET. It recruited individuals with Subjective Cognitive Decline plus (SCD+), and syndromic diagnosis of Mild Cognitive Impairment (MCI) and dementia. Here, we describe the...

Background Self‐reflection is conceptualised as an introspective process that involves active evaluation of one’s thoughts, feelings and behaviours. Engagement in self‐reflection is thought to yield more adaptive stress responses, that in turn result in better short‐term (e.g., reduced inflammatory responses to stressors) and long‐term (e.g., recov...

Up to 40% of dementias may be preventable via risk factor modification. This inference has motivated the development of lifestyle interventions for reducing cognitive decline. Typically delivered to older adults face-to-face, the COVID-19 pandemic has necessitated their adaptation for remote delivery. We systematically reviewed randomized controlle...

Introduction: People living with dementia in nursing homes have complex needs; impairments in cognition, communication, and daily function; neuropsychiatric symptoms (NPS); and poor quality of life (QoL). The current study examines impairments in non-verbal communication as a potential driver of NPS and QoL. Methods: One hundred nursing home res...

Introduction: Older adults experiencing subjective cognitive decline (SCD) have a heightened risk of developing dementia and frequently experience subclinical anxiety, which is itself associated with dementia risk. Objective: To understand whether subclinical anxiety symptoms in SCD can be reduced through behavioral interventions. Methods: SCD...

Background Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated. Here we evaluated the influence of insulin resistance on brain glucose metabolism, grey matter volume and white matter...

Purpose The aim of this study was to re-evaluate the differentiation of patients with dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD) and Parkinson’s disease (PD) using a quantitative analysis of ¹²³ I-FP-CIT SPECT scans. Methods Thirty-six patients with in vivo ¹²³ I-FP-CIT SPECT and neuropathological diagnoses were included. Based...

Dementia with Lewy bodies (DLB) is the second most common form of degenerative dementia. However, it can be difficult to diagnose as it shares common features with both Alzheimer’s disease (AD) and Parkinson’s disease (PD). Early detection as well as accurate differentiation from other types of dementia are essential to inform management and treatm...

Recent data-sharing initiatives of clinical and preclinical Alzheimer’s disease (AD) have led to a growing number of non-clinical researchers analyzing these datasets using modern data-driven computational methods. Cognitive tests are key components of such datasets, representing the principal clinical tool to establish phenotypes and monitor sympt...

Background Late onset depression (LOD) may precede the diagnosis of Parkinson’s disease (PD) or dementia with Lewy bodies (DLB). We aimed to determine the rate of clinical and imaging features associated with prodromal PD/DLB in patients with LOD. Methods In a cross-sectional design, 36 patients with first onset of a depressive disorder (Diagnosti...

Next-generation genetic sequencing (NGS) technologies facilitate the screening of multiple genes linked to neurodegenerative dementia, but there are few reports about their use in clinical practice. Which patients would most profit from testing, and information on the likelihood of discovery of a causal variant in a clinical syndrome, are conspicuo...

Background Observational findings suggest that a third of dementia cases are attributable to modifiable risk factors (Livingston et al, 2017). However, we are still unclear on what non‐pharmacological interventions should look like or what a manualised dementia prevention programme might include. Method PubMed, EMBASE (Ovid), PsycINFO, CINAHL, Web...

Background Cerebral metabolic rate of glucose (CMRglc) can be measured with fluorodeoxyglucose (FDG) positron emission tomography (PET) using arterial blood sampling. However, blood sampling is an invasive methodology for subjects. Standard uptake value (SUV) is a non‐invasive method to assess the cerebral glucose metabolism. Here we evaluate the r...

Background Many people live with an awareness of mild cognitive changes and an associated dementia risk. Previous authors describe the uncertainties of this liminal state between cognitive health and dementia. The interface of this group with health services is growing, driven by early dementia diagnosis campaigns and research about the preventativ...

Background 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) measures regional cerebral glucose metabolism –which is a biomarker of neuronal function in Alzheimer’s disease (AD) Neuropsychological measures such as the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS‐Cog) – a measure of memory, language and praxis has been...

Background Brain atrophy can be reliably measured through volumetric analysis of structural MRI and is a valid biomarker of neurodegeneration in Alzheimer’s disease (AD) pathology ¹ . The Alzheimer’s Disease Assessment Scale‐Cognitive subscale (ADAS‐Cog12) is a neuropsychological test designed to assess the level of cognitive dysfunction in AD with...

Background AMYPAD‐DPMS is the largest European, multicenter, prospective and randomized study assessing clinical utility and cost‐effectiveness of amyloid‐PET in a controlled but realistic clinical setting. In the present abstract we report preliminary results on the baseline features of the first study participants. Method A total of 900 particip...

Background Amyloid‐PET is increasingly used for diagnostic purposes in patients with cognitive impairment due to suspected Alzheimer’s disease. However, cognitively unimpaired individuals are frequently included in research studies involving amyloid‐PET scan. Even if amyloid‐PET is not clinically recommended in these cases, these patients often wan...

Background The primary focus of mindfulness‐based program (MBP) research to date has been on mental health. More recently, attention has turned to putative effects on cognition. An evidence synthesis is required to answer the key question of ‘Do MBPs confer cognitive benefit, and if so, for whom?’ A particularly crucial distinction is whether benef...

Background Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent in Alzheimer’s disease (AD) and associated with adverse outcomes. There is increasing interest in identifying the risk factors for developing BPSD among AD patients. However, the pathophysiological mechanisms underlying BPSD remain poorly understood. Here we ev...

Introduction: Fifteen percent of people with mild cognitive impairment (MCI) will progress to dementia within 2 years. There is increasing focus on the evaluation of biomarkers which point towards the underlying pathology. This enables better prediction of clinical outcomes. Early diagnosis of the dementia subtype is crucial for appropriate manage...

An amendment to this paper has been published and can be accessed via the original article.

Objectives Many people live with an awareness of mild cognitive changes that increase their dementia risk. Previous authors describe the uncertainties of this liminal state, between cognitive health and dementia, where being “at risk” can itself be an illness. We ask how services respond to people with memory concerns currently, and how a future, e...

It is unclear what non-pharmacological interventions to prevent cognitive decline should comprise. We systematically reviewed lifestyle and psychosocial interventions that aimed to reduce cognitive decline in healthy people aged 50+, and people of any age with Subjective Cognitive Decline or Mild Cognitive Impairment. We narratively synthesised evi...

The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive impairment (MCI), (2) delirium-onset, and (3) psychiatric-onset presentations. The purpose of our review is to determine whether there is sufficient information yet available to justify development of diagnostic criteria for each of these. Our goal is to achieve evid...

Background: Observational studies indicate that approximately a third of dementia cases are attributable to modifiable cardiometabolic, physical and mental health, social and lifestyle risk factors. There is evidence that intensive behaviour change interventions targeting these factors can reduce cognitive decline. Methods and analysis: We will...

The increasing global prevalence of dementia and the lack of disease-modifying treatments give rise to the need for early detection of dementia-causing diseases to enable the development and targeted administration of preventative interventions. However, current methods that have potential for the early detection of dementia-causing diseases, such...

Background: The START (STrAtegies for RelaTives) intervention reduced depressive and anxiety symptoms of family carers of relatives with dementia at home over 2 years and was cost-effective.AimsTo assess the clinical effectiveness over 6 years and the impact on costs and care home admission. Method: We conducted a randomised, parallel group, sup...

A concise and up-to-date text on the mental health of older people, this second edition is fully updated to reflect changes in technology, competency-based training, guidelines, law and treatments. Each chapter sits alone as an informative, readable and helpful resource for a range of health care professionals. Together the chapters form an essenti...

Uncertainties remain around the use of biomarkers in clinical practice to diagnose Alzheime's disease. There are several implications for both patients and clinicians, including the ethical and practical dilemmas of identifying a disease process early in its course when there are no disease‐modifying treatments available.

A concise and up-to-date text on the mental health of older people, this second edition is fully updated to reflect changes in technology, competency-based training, guidelines, law and treatments. Each chapter sits alone as an informative, readable and helpful resource for a range of health care professionals. Together the chapters form an essenti...

Background There is only limited information available about the effect of age on course of cognitive decline in patients with onset of Alzheimer’s disease (AD) over the age of 64 years. Objective We compared the rate of, and factors affecting, cognitive decline in patients with AD aged < 65 years (young-onset AD), 65–74 years (middle-onset AD), a...

Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing...